Table 1.

Socio-demographic, psychometric and prostate cancer characteristics of study participants.

Characteristic	Count	Characteristic	Count
Age (n = 349), mean (SD) (survey) Relationship status (n = 349), n (%) (survey)  • With partner  • Without partner Country of birth (n = 349), n (%) (survey)  • Australia  • Overseas Residence (n = 349), n (%) (survey)  • Major city  • Regional/remote Education (n = 349), n (%) (survey)  • Primary/secondary school  • University/vocational college Income (n = 312), n (%) (survey)  • <AUD 50,000  • ≥50,000 Employment (n = 349), n (%) (survey)  • Working  • Retired Government pension/disability support (n = 346), n (%) (survey)  • Yes  • No Age at PCx diagnosis (n = 349), mean (SD) (survey) EAU risk stratification (clinical stage) (n = 297), n (%) (rooms)  • Low  • Intermediate/high Second opinion from health practitioner (n = 349), n (%) (survey)  • Yes  • No	• 69.6 (7.8) • 307 (88) • 42 (12) • 267 (76.5) • 82 (23.5) • 239 (68.5) • 110 (31.5) • 87 (24.9) • 262 (75.1) • 84 (26.9) • 228 (73.1) • 157 (45) • 192 (55) • 82 (23.7) • 264 (76.3) • 65.4 (7.8) • 100 (33.7) • 197 (69.3) • 98 (28.1) • 251 (71.9)	First treatment (localized disease) (n = 331), n (%) (rooms) • Active surveillance • Active treatment (surgery, radiotherapy, ADT) Active surveillance failure (n = 103), n (%) (rooms) • Yes • No Biochemical failure (n = 349), n (%) (rooms) • Yes • No Locally advanced/metastatic at any time (n = 349), n (%) (rooms) • Yes • No Decision Regret Scale (n = 339), mean (SD) PHQ-9 scale (n = 346), mean (SD) • No symptoms (summative score < 5), n (%) • Mild (summative score 5–9), n (%) • Moderate (summative score 10–14), n (%) • Moderate–severe (summative score 15–19), n (%) • Severe (summative score > 19), n (%) GAD-7 scale (n = 346), mean (SD) • No symptoms (summative score < 4), n (%) • Mild (summative score 5–9), n (%) • Moderate (summative score 10–14), n (%) • Severe (summative score > 14), n (%) GSES scale (n = 346), mean (SD) Peer navigator for digital PCx information (n = 346), n (%) (survey) • Yes • No EORTC QLQ-C30 functional TCI met (n = 349), n (%) (survey) • Yes • No EORTC QLQ-C30 symptom TCI met (n = 349), n (%) (survey) • Yes • No	• 103 (31.1) • 228 (68.9) • 55 (53.4) • 48 (46.6) • 49 (14) • 300 (86) • 35 (10) • 314 (90) • 8.5 (15.6) • 2.7 (3.4) • 274 (79.2) • 53 (15.3) • 15 (4.3) • 3 (0.9) • 1 (0.3) • 2 (3.1) • 284 (82.1) • 53 (15.3) • 6 (1.7) • 3 (0.9) • 32.5 (4.2) • 110 (31.8) • 236 (68.2) • 103 (29.5) • 246 (70.5) • 215 (61.6) • 134 (38.4)